Bristol-Myers Squibb Company vs Broadcom Inc.: Strategic Comparison

This in-depth comparison examines Bristol-Myers Squibb Company and Broadcom Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bristol-Myers Squibb Company on its own, evaluating Broadcom Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bristol-Myers Squibb Company and Broadcom Inc. is widest.

On the headline numbers, Bristol-Myers Squibb Company reports annual revenue of $48.2B against $63.9B for Broadcom Inc., while their respective market capitalizations stand at $127.5B and $1.68T. Both Bristol-Myers Squibb Company and Broadcom Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Broadcom Inc.: Much of the internet runs on Broadcom parts that users never see. Its chips route traffic inside cloud data centers, connect phones and laptops to Wi-Fi, and run cable and fiber gateways, while its VMware software runs a large share of corporate private clouds. Since 2024 the company's identity has shifted toward AI: custom accelerators and AI networking went from about $12 billion of revenue in fiscal 2024 to $16.7 billion in a single quarter in 2026.

Bristol-Myers Squibb Company and Broadcom Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bristol-Myers Squibb Company and Broadcom Inc..

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

Broadcom Inc. business model: Broadcom reports two segments. Semiconductor Solutions sold $36.9 billion of chips in fiscal 2025: custom AI accelerators (XPUs) designed with hyperscale customers, Tomahawk and Jericho Ethernet switch chips, network adapters, optical components, Wi-Fi and Bluetooth chips, RF filters for smartphones, broadband gateway chips and storage connectivity. Infrastructure Software brought in $27.0 billion, mostly VMware Cloud Foundation subscriptions plus mainframe, security and automation software from CA and Symantec. Most advanced chips are made by outside foundries, chiefly TSMC. The mix is moving quickly toward AI: in the third quarter of fiscal 2026 semiconductors were 70% of revenue, and AI chips alone were $16.7 billion of the $29.6 billion total.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bristol-Myers Squibb Company stack up against those of Broadcom Inc..

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Broadcom Inc. competitive advantage: Broadcom's edge is engineering depth in a few hard problems where customers rarely switch once a design is chosen: high-speed SerDes, switch silicon, advanced packaging and custom ASIC design. Its Tomahawk 6 switch chip, announced in June 2025, handles 102.4 terabits per second. In software, VMware is built into enterprise data centers, which makes migrations slow and costly. Scale reinforces both: fiscal 2025 free cash flow of $26.9 billion pays for R&D, dividends and debt reduction at the same time.

Future prospects matter as much as current results. The growth strategies below explain how Bristol-Myers Squibb Company and Broadcom Inc. each plan to expand from here.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

Broadcom Inc. growth strategy: Broadcom's growth plan has two engines. In chips, it co-designs custom accelerators with a short list of customers, including Google's TPU, Meta's MTIA, OpenAI and Anthropic, and sells the Ethernet switches, network adapters and optics that connect them. In software, it is moving VMware's installed base onto VMware Cloud Foundation subscriptions; VCF 9.0 shipped in June 2025 as a private-cloud alternative to the public cloud, and infrastructure software revenue rose 29% to $8.8 billion in the third quarter of fiscal 2026. Acquisitions, the historic third engine, have been on hold while VMware debt is paid down.

A closer look at the financial trajectory of Bristol-Myers Squibb Company and Broadcom Inc. rounds out the comparison.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.

Broadcom Inc.: Fiscal 2025 revenue rose 24% to $63.9 billion and net income reached $23.1 billion, up from $5.9 billion in fiscal 2024, when a large income tax charge weighed on results. Operating income was $25.5 billion and free cash flow $26.9 billion, of which $11.1 billion went to dividends and $6.4 billion to buybacks. Fiscal 2026 then accelerated: quarterly revenue went from $19.3 billion in Q1 to $22.2 billion in Q2 and $29.6 billion in Q3, with Q4 guided at about $34.8 billion. Long-term debt taken on for VMware fell to $57.2 billion at 2 August 2026 from $62.0 billion at the end of fiscal 2025, and the quarterly dividend is $0.65 a share after a 10% increase.